3P Biopharmaceuticals: building a legacy of innovation and excellence in biotechnology
News and updates
All
Biovian announces the successful refinancing of its existing debt package and the securing of new funding to support GeneCity facility expansion
Biovian Unveils the Stonemasonry Work of GeneCity Facility
3P Biopharmaceuticals and the University of Navarra bring the Neanderthal world and biomedicine to the public in a successful event.
3P Biopharmecuiticals celebrates cerebral palsy day in collaboration with ASPACE
3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.
Biovian announces over €50 million investment in manufacturing facility in Turku, Finland
3P Biopharmaceuticals lands in the United States.
3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.
The Regional Minister for Economic and Business Development Mikel Irujo meets with the management of 3P Biopharmaceuticals and its majority shareholder Keensight Capital.
3PBIOVIAN’s in-house Solution preparation team prepares and provides a wide variety of solutions
3P Biopharmaceuticals is moving forward with its expansion plan and the adaptation of its facilities.
3P Biopharmaceuticals increases its microbial production capacity with the installation of a 500 L fermenter.
3P Biopharmaceuticals among the 500 fastest growing companies in Spain
3P Biopharmaceuticals brings together leading international experts in biomedicine to celebrate its 15th anniversary.
Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS-COV-2